TERF1 and lung adenocarcinoma: Furthermore, we have shown that “in vivo” treatment of already established lung adenocarcinomas with one of the identified compounds, ETP-47037, results in decreased TRF1 signal in vivo and the impairment of tumor progression in the absence of decreased mouse viability.